Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,856Revenue $M3.6Net Margin (%)-3,237.2Altman Z-Score49.5
Enterprise Value $M2,499EPS $-1.3Operating Margin %-3,334.9Piotroski F-Score5
P/E(ttm)--Beneish M-Score-1.8Pre-tax Margin (%)-3,237.2Higher ROA y-yY
Price/Book7.710-y EBITDA Growth Rate %--Quick Ratio17.2Cash flow > EarningsY
Price/Sales7155-y EBITDA Growth Rate %--Current Ratio17.2Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-38.3Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-42.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M98.5ROIC % (ttm)-786.6Gross Margin Increase y-yN

Gurus Latest Trades with CLDX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CLDXJoel Greenblatt 2015-03-31 Buy 0.01%$18.29 - $31.78
($23.85)
$ 29.0022%New holding35,223
CLDXFirst Eagle Investment 2014-12-31 Add0.01%$12.55 - $20.93
($16.61)
$ 29.0075%Add 123.82%559,542
CLDXFirst Eagle Investment 2014-09-30 Buy 0.01%$12.05 - $17.57
($14.51)
$ 29.00100%New holding250,000
CLDXFirst Eagle Investment 2014-03-31 Sold Out -0.01%$16.95 - $31.59
($25.6)
$ 29.0013%Sold Out0
CLDXFirst Eagle Investment 2013-12-31 Reduce-0.04%$21.51 - $36.71
($25.51)
$ 29.0014%Reduce 75.45%135,000
CLDXFirst Eagle Investment 2013-06-30 Reduce-0.02%$11.01 - $16.09
($13.13)
$ 29.00121%Reduce 45.89%665,560
CLDXGeorge Soros 2012-06-30 Sold Out -0.06%$3.9 - $5.26
($4.39)
$ 29.00561%Sold Out0
CLDXFirst Eagle Investment 2012-06-30 Add0.02%$3.9 - $5.26
($4.39)
$ 29.00561%Add 260.87%1,660,000
CLDXGeorge Soros 2012-03-31 Buy 0.06%$2.77 - $5.46
($4)
$ 29.00625%New holding803,200
CLDXFirst Eagle Investment 2012-03-31 Add0.01%$2.77 - $5.46
($4)
$ 29.00625%Add 360.00%460,000
CLDXFirst Eagle Investment 2011-12-31 Reduce$2.11 - $3.21
($2.7)
$ 29.00974%Reduce 71.43%100,000
CLDXFirst Eagle Investment 2011-06-30 Buy 0.01%$3.03 - $4.46
($3.75)
$ 29.00673%New holding350,000
CLDXFirst Eagle Investment 2010-03-31 Sold Out $4.35 - $6.39
($4.93)
$ 29.00488%Sold Out0
CLDXFirst Eagle Investment 2009-12-31 Buy $4.2 - $5.66
($4.78)
$ 29.00507%New holding100,000
CLDXFirst Eagle Investment 2009-09-30 Sold Out $4.95 - $7.93
($6.35)
$ 29.00357%Sold Out0
CLDXFirst Eagle Investment 2009-06-30 Buy $6.81 - $11.22
($8.56)
$ 29.00239%New holding50,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CLDX is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


CLDX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
van den Broek RichardDirector 2014-12-17Sell0$0view
LIPTON KAREN SHOOSDirector 2013-12-06Sell17,728$24.518.37view
PENNER HARRY JRDirector 2013-12-06Sell17,728$24.518.37view
ELLBERGER LARRYDirector 2013-12-06Sell17,728$24.518.37view
CATLIN AVERY WSr. VP & CFO 2013-12-06Sell183,333$24.518.37view
KELER TIBORSr. VP & CSO 2011-08-11Buy5,000$2.51060view
Marucci Anthony SPresident & CEO 2011-08-09Buy15,000$2.411103.32view
CATLIN AVERY WSr. VP & CFO 2011-08-09Buy2,000$2.391113.39view
LIPTON KAREN SHOOSDirector 2010-09-16Buy3,000$3.74675.4view
Davis Thomas AndrewSr. VP & CMO 2010-09-16Buy2,500$3.77669.23view

Press Releases about CLDX :

    Quarterly/Annual Reports about CLDX:

    News about CLDX:

    Articles On GuruFocus.com
    Roth Capital Weighs In On 5 Biotech Stocks to Watch Apr 05 2015 
    Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
    CLDX up 223%, Cohen Gains Big Apr 23 2013 
    Steve Cohen Increases Celldex Up 145% Apr 06 2013 
    comment on CLDX Mar 06 2013 
    5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
    CELLDEX THERAPEUTICS, INC (CLDX) CEO Anthony S Marucci buys 12,000 Shares Sep 13 2010 
    Weekly CFO Buys Highlight: GNMK, RTIX, BKOR, PTEK, CLDX Sep 12 2010 
    CELLDEX THERAPEUTICS, INC Reports Operating Results (10-Q) Aug 05 2010 
    CELLDEX THERAPEUTICS, INC Reports Operating Results (10-Q) May 06 2010 

    More From Other Websites
    Celldex Therapeutics Initiates Phase 1/2 Study of Varlilumab in Combination with Sunitinib in... May 28 2015
    9:26 am Celldex Therapeutics announces the initiation of an open-label, Phase 1/2 safety and... May 28 2015
    Celldex Therapeutics Initiates Phase 1/2 Study of Varlilumab in Combination with Sunitinib in... May 28 2015
    Celldex Therapeutics to Present at the Jefferies 2015 Global Healthcare Conference May 27 2015
    Celldex Therapeutics to Present at the Jefferies 2015 Global Healthcare Conference May 27 2015
    Biotech Stock Mailbag: ASCO Preview, CAR-T stocks, MannKind, Hate Mail! May 22 2015
    Celldex Therapeutics to Present Data from the ReACT Study at 2015 ASCO Annual Meeting May 13 2015
    Celldex Therapeutics to Present Data from the ReACT Study at 2015 ASCO Annual Meeting May 13 2015
    Research Reports May 01 2015
    10-Q for Celldex Therapeutics, Inc. May 01 2015
    Celldex 1Q Loss Narrower-Than-Expected, Pipeline in Focus - Analyst Blog Apr 29 2015
    Celldex Reports First Quarter 2015 Results Apr 29 2015
    Celldex reports 1Q loss Apr 29 2015
    Celldex reports 1Q loss Apr 29 2015
    CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Apr 29 2015
    Celldex Reports First Quarter 2015 Results Apr 29 2015
    Celldex Therapeutics (CLDX) Crumbles: Stock Slumps by 15.9% - Tale of the Tape Apr 28 2015
    Celldex's Varlilumab Demonstrates Synergistic Anti-Tumor Activity with PD-1 Signaling Blockade in... Apr 20 2015
    Celldex's Varlilumab Demonstrates Synergistic Anti-Tumor Activity with PD-1 Signaling Blockade in... Apr 20 2015
    Exelixis' Cometriq Gets Fast Track Status in U.S. - Analyst Blog Apr 10 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK